Related Experiment Video
Updated: May 23, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy
Ghada T Ballane1, Jad G Sfeir, Habib A Dakik
1Division of Endocrinology and Metabolism, American University of Beirut Medical Center, Beirut, Riad El Solh, Lebanon.
Insights
Severe hypocalcemia from hypoparathyroidism can cause heart failure. Early treatment, including recombinant human parathyroid hormone (PTH), significantly improved cardiac function in a rare case.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Disorders
Background:
- Hypoparathyroidism, often resulting from thyroidectomy, can lead to severe hypocalcemia.
- Hypocalcemia is a rare but significant cause of congestive heart failure (CHF).
- Prompt diagnosis and management are crucial for improving cardiac function.
Observation:
- A middle-aged woman presented with heart failure symptoms 22 years post-thyroidectomy.
- She exhibited profound hypocalcemia (serum calcium 3.7 mg/dl) and hyperphosphatemia (serum inorganic phosphate 17.6 mg/dl).
- This clinical picture indicated hypocalcemia secondary to hypoparathyroidism.
Findings:
- The patient received standard calcium and calcitriol supplementation.
- She was the first reported case of severe hypocalcemic cardiomyopathy treated off-label with recombinant human parathyroid hormone (PTH).
- Treatment led to significant improvement in cardiac function.
Implications:
- This case highlights the critical role of calcium and PTH in myocardial contractility.
- It suggests potential therapeutic benefits of PTH in managing hypocalcemic cardiomyopathy.
- Understanding these mechanisms is vital for diagnosing and treating rare causes of heart failure.
Abstract:
Hypocalcemia secondary to hypoparathyroidism is a rare cause of congestive heart failure. However, its early recognition and treatment lead to significant improvement in cardiac function. We report a middle-aged woman presenting with symptoms of heart failure with a serum calcium level of 3.7 mg/dl and a serum inorganic phosphate level of 17.6 mg/dl 22 years after subtotal thyroidectomy. Besides calcium and calcitriol supplementation, she was the first patient with severe hypocalcemic cardiomyopathy to be given off-label recombinant human parathyroid hormone (PTH) because of an elevated serum calcium-phosphate product. We discuss the management and outcome of the patient and then present a brief review of similar previously reported cases. We also describe the pivotal role of calcium ion and the potential role of PTH in maintaining myocardial contractility, effective natriuresis, and possible pathogenic mechanisms contributing to heart failure secondary to hypocalcemia and hypoparathyroidism.
More Related Videos
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...